e-ISSN: 2319-9865
p-ISSN: 2322-0104

Research & Reviews: Journal of Medical and Health Sciences

A Review on Parkinson's Disease

Ajlan A*

Amity Institute of Biotechnology, Sector – 125 Noida – 201303, UP, India

Review Article

Received: 23/08/2016
Accepted: 29/08/2016
Published: 31/08/2016

***For Correspondence**

Ajlan A, Amity Institute of Biotechnology, Sector – 125 Noida – 201303, UP, India, Tel: +919873118691.

E-mail: akhtarajlan@gmail.com

Keywords: Parkinsonism, Neurotransmitters, Motor system, Dopaminergic, Environmental factors.

ABSTRACT

Parkinson's disease is a neurological issue with developing layers of multifaceted nature. It has long been portrayed by the classical motor features of Parkinsonism connected with Lewy bodies and loss of dopaminergic neurons in the substantia nigra. However, symptomatology of Parkinson's disease is presently perceived as heterogeneous, with clinically significant non-motor features. Correspondingly, its pathology includes broad regions of the sensory system, different neurotransmitters, and protein totals other than just Lewy bodies. The reason for Parkinson's disease stays obscure, yet danger of building up Parkinson's disease is no more seen as fundamentally because of environmental factors. Rather, Parkinson's disease appears to come about because of a complicated interaction of hereditary and environmental factors influencing various major cell forms. The unpredictability of Parkinson's disease is accompanied by clinical difficulties, including a failure to make a conclusive determination at the most punctual phase of the sickness and troubles in the management of indications at later stages.

INTRODUCTION

Parkinson's disease (PD) is a typical neurodegenerative disorder with a commonness of 160/100 000 in Western Europe ascending to ~ 4% of the population more than 80 [1-5]. Parkinson's disease is a dynamic neurodegenerative issue, which is described by motor side effects, for example, tremor, inflexibility, slowness of movement and issues with step [6-10]. Motor side effects are frequently accompanied with weakness, depression, pain and cognitive problems. With a maturing population, the administration of Parkinson's disease is likely to prove an increasingly important and challenging aspect of medical practice for neurologists and general physicians. Our comprehension of the pathogenesis of the disease has been progressed in the most recent decade with the distinguishing proof of a few quality changes which may reveal insight into the components of pathogenesis in sporadic instances of Parkinson's disease [10-20]. The diagnosis of Parkinson's disease remains basically a clinical one, and it is essential to perceive the early components together with side effects and signs proposing different reasons for Parkinsonism. There has likewise been a quick expansion in the treatment choices both in the early and in the later phases of the ailment together with a more awareness of non-motor complications [21-25].

CAUSES OF PARKINSON'S DISEASE

To date, in spite of many years of concentrated study, the reasons for Parkinson's stay obscure. Numerous specialists imagine that the disease is brought about by a blend of hereditary and environmental components, which may vary from individual to individual. In a few people, hereditary variables may assume a part; in others, ailment, an environmental toxins or other occasion may add to Parkinson's sickness. Researchers have recognized maturing as an imperative danger factor; there is a two to four percent risk for Parkinson's among individuals over age 60, contrasted with one with two percent in the all general community [26-30].

Genetic Factors

Most by far of Parkinson's cases are not directly acquired. Around 15% to 25% of individuals with Parkinson's report having a relative with the illness. In vast population studies, specialists have found that individuals with an

influenced first-degree relative, for example, a guardian or kin, have a four to nine percent higher chance of building up Parkinson's ailment, when contrasted with the all general community. This implies if a person's guardian has Parkinson's sickness, his or her chances of building up the illness are marginally higher than the danger among the overall public [31-40].
Scientists have found a few gene mutations that can bring about the infection specifically; however these influence just a little number of families. Some of these mutations include genes that assume a part in dopamine cell functions. Parkinson's has developed at an early age in people with transformations in genes for parkin, PINK1, LRRK2, DJ-1 and glucocerebrosidase, among others. Since hereditary types of an ailment can be studied on in incredible point of interest in the lab, and in light of the fact that comprehension the uncommon hereditary types of Parkinson's may help us to see more basic forms of the ailment, hereditary qualities is as of now the subject of intense research [41-45].

Environmental Factors

Various environmental elements have been connected with an increased danger of Parkinson's including: pesticide introduction, head wounds, and living in the nation or farming. Rural environments and the drinking of well water might be dangers as they are aberrant measures of presentation to pesticides [46-50].
Involved specialists incorporate bug sprays, principally chlorpyrifos and organochlorines and pesticides, for example, rotenone or paraquat and herbicides, for example, Agent Orange and ziram. Heavy metals introduction has been proposed to be a danger factor, through conceivable gathering in the substantia nigra; in any case, studies on the issue have been uncertain [51-60].
A few researchers have proposed that Parkinson's disease may come about because of introduction to an environmental poison or injury. Epidemiological research has distinguished a few elements that might be connected to Parkinson's, including rural living, well water, manganese and pesticides. A few studies have shown that prolonged occupational exposure to specific chemicals is connected with a lifted danger of Parkinson's disease. These incorporate the insecticides permethrin and beta-hexachlorocyclohexane (beta-HCH), the herbicides paraquat and 2,4-dichlorophenoxyacetic corrosive and the fungicide maneb [61-70].

CLINICAL DIAGNOSIS OF PARKINSON'S DISEASE

The characteristic elements of Parkinson's malady are bradykinesia, rigidity and rest tremor. These may not all be available. Postural instability might be an element, however early postural instability in reverse especially with a past filled with falls is more suggestive of progressive supranuclear paralysis (PSP). The clinical discoveries are normally asymmetrical in Parkinson's illness [71-73]. The clinical analysis may frequently seem clear, however it is important that post-mortem studies have shown an alternative diagnosis in up to a quarter of patients with Parkinson's disease diagnosed by general neurologists.. Of note, there is significantly less diagnostic blunder in patients analyzed in expert movement disorder clinics which fortifies the argument for early referral of patients to authorities master in movement disorders [74,75].
There are various other clinical signs that worth highlighting. A change of handwriting with micrographia is regularly an early component as is reduced facial expression. Lost arm swing on one side is likewise an early and valuable diagnostic feature. A glabellar tap does not appear to be especially sensitive or particular [76-79].
A decreased feeling of smell is, however, worth getting some information about since this might be one of the main side effects in early Parkinson's malady. As the ailment turns out to be more exceptional, hypophonia, drooling of salivation (from decreased gulping) and debilitation of postural reflexes may develop [80]. Non-motor complications of the ailment frequently turn out to be more troublesome as the sickness progresses. It is useful to enquire about side effects of depression which happens in ~ 40% of Parkinson's illness patients. In spite of the fact that the diagnosis of Parkinson's infection is a clinical one, there are sure circumstances where examinations can demonstrate valuable. Ordinary mind imaging with MRI or CT is typically not required unless an alternative diagnosis is suspected, for example, normal pressure hydrocephalus or vascular Parkinsonism [81-85].
Single photon emission computerized tomography (SPECT) imaging utilizing a dopamine transporter (DAT) can be useful in separating Parkinson's malady from various conditions, including crucial tremor and dystonic tremor, neuroleptic-induced Parkinsonism and psychogenic Parkinsonism all of which show typical DAT scans. Uptake inside the basal ganglia is lessened in Parkinson's sickness, the parkinsonian disorders and DLB [86-89].

PREVENTION

Exercise in middle age reduces the risk of Parkinson's disease later in life. Caffeine also appears protective with a greater decrease in risk occurring with a larger intake of caffeinated beverages such as coffee. Although tobacco smoke causes adverse health effects, decreases life expectancy and quality of life, it may reduce the risk of Parkinson's disease by a third when compared to non-smokers [90]. The basis for this effect is not known, but

possibilities include an effect of nicotine as a dopamine stimulant. Tobacco smoke contains compounds that act as MAO inhibitors that also might contribute to this effect [91-93].
Antioxidants, such as vitamins C and D, have been proposed to protect against the disease but results of studies have been contradictory and no positive effect has been proven. The results regarding fat and fatty acids have been contradictory, with various studies reporting protective effects, risk-increasing effects or no effects. Also, there have been preliminary indications of a possible protective role of estrogens and anti-inflammatory drugs [94].

MANAGEMENT OF EARLY PARKINSON'S DISEASE

After building up a clinical diagnosis, it is basic to take time to clarify the condition and its suggestions to the patient and relatives. It might require for a few patients time to deal with and acknowledge the diagnosis. Connecting patients with Parkinson's illness medical attendant pros and Parkinson's sickness beneficent associations, if accessible locally, can be greatly useful [95].
The planning when to begin drug treatment in Parkinson's ailment, especially in the early phases of the ailment, when there might be minimal functional deficit can be difficult. The choice which ought to be made with full inclusion of the patient is controlled by the level of physical impairment adjusted against the complexities that can be identified with medication treatment. Of expanding significance is the issue of whether early treatment gives the potential for neuroprotection. This remaining parts uncertain, regardless of countless vitro, in vivo and human studies huge numbers of the last utilizing PET or SPECT imaging as surrogate markers of nigrostriatal dopaminergic function.
At present, hence, there are no demonstrated neuroprotective treatments with just symptomatic medications available.
In the event that the patient and clinician feel treatment is required, what treatment ought to be initiated? This choice will be based on the age of the patient, the probability of appropriate consistence, the nearness of psychological disability, extra medicinal conditions and the desires of the patient. Treatment in the underlying stage is to l alleviate symptom permitting the person to be completely free and to do their typical every day activities. It is indispensable that treatment is very much endured. Therefore, monotherapy is typically desirable. In the event that patients can stay on treatment with negligible reactions, with an acceptable decrease of symptoms and a sentiment prosperity that permits them to live freely and beneficially, then the introduction of treatment has clearly been advantageous [96,97].

CONCLUSION

Parkinson's sickness is a typical neurodegenerative disease. A mix of hereditary and environmental factors is liable to be vital in delivering unusual protein collection inside select gatherings of neurons, prompting cell brokenness and after then death. The diagnosis remains a clinical one, and there ought to be a high index of suspicion to avoid different causes for Parkinsonism [98]. A substantial number of agents together with surgical interventions are presently accessible to treat early and late complications of Parkinson's ailment. Expanding consideration is being given to the determination and treatment of non-motor complexities in Parkinson's illness. Future advancements in Parkinson's malady are liable to concentrate on the idea of sickness altering drugs which offer neuroprotection [99,100].

REFERENCES

1. Kim HD, et al. Omics as therapeutic platform: Environmental factors to Parkinson's disease. J Microb Biochem Technol. 2016;8:222-225.
2. Cannas A, et al. Suicide in Parkinson's disease: An open question and a complex and poorly explored phenomenon. J Neurol Disord. 2016;4:273.
3. Mirek E, et al. Analysis of postural stability in a female-patient with Parkinson's disease before and after double-sided dbs implantation a 2 year case-study. Gen Med (Los Angeles). 2016;4:254.
4. Eggert K, et al. A prospective, multicenter, 2-year echocardiographic study on valvular heart disease in Parkinson's disease patients taking rotigotine and other non-ergot dopamine agonists. J Alzheimer's Dis Parkinsonism. 2016;6:233.
5. Ikemoto K. Imaging of d-cell: aromatic l-amino acid decarboxylase (aadc)-immunoreactive glial cell found in parkinsonian striatum. J Mol Imag Dynamic. 2016;6:i103.

6. Akamatsu M, et al. Overnight monitoring of turnover movements in Parkinson's disease using a wearable three-axis accelerometer. J Neurol Disord. 2016;4:267.
7. Sugama S, et al. Effect of chronic stress in the onset of Parkinson's disease: Possible role of microglial cells in neuroinflammation. J Neurol Disord. 2015;S2:001.
8. Hiller ALP, et al. Are cholinesterase inhibitors effective in improving balance in Parkinson's disease? J Neurol Disord. 2015;S2:002.
9. Kataoka H and Ueno S. Frontal assessment battery and falling related with freezing of gait in Parkinson's disease. Int J Phys Med Rehabil. 2016;4:335.
10. Zeilig G and Shiller AD. Advanced technology to enhance rehabilitation outcomes: Parkinson's disease. Int J Neurorehabilitation. 2016;3:e124.
11. Woolhouse MH and Zaranek A. Intuitive navigation in computer applications for people with Parkinson's. J Biomusic Eng. 2016;4:115.
12. Biswas A and Das SK. Alzheimer and Parkinson's disease - two faces of the same disease? J Alzheimers Dis Parkinsonism. 2016;6:222.
13. Prasad RKA, et al. A review on techniques for diagnosing and monitoring patients with Parkinson's disease. J Biosens Bioelectron. 2016;7:203.
14. Werner FM and Coveñas R. Efficacy of the deep-brain stimulation in Parkinson's disease according to a neural network. J Cytol Histol. 2016;S5:S5-010.
15. Kaut O, et al. DNA methylation of imprinted loci on autosomal chromosomes and igf2 are not affected in Parkinson's disease patients peripheral blood monocytes. Brain Disord Ther. 2016;5:211.
16. Peacock CA, et al. Effects of an exercise intervention on body composition in older adult males diagnosed with Parkinson's disease: A brief report. Physiother Rehabil. 2016;1:102.
17. Pieroni MA and Pieroni PG. Novel therapeutic approach for Parkinson's disease during rem sleep. J Health Edu Res Dev. 2016;4:164.
18. Birman N, et al. Decreased dopamine transporter binding ipsilateral to the clinically more affected side in Parkinson's disease: Which side to take? J Neurol Neurophysiol. 2016;7:361.
19. Vecchis RD, et al. non-ergot- dopamine agonists don't increase the risk of heart failure in Parkinson's disease patients. A meta-analysis of randomized controlled trials. J Pharmacovigilance. 2016;4:197.
20. Bayle N, et al. Movement smoothness differentiates voluntary from parkinsonian bradykinesia. J Addict Res Ther. 2016;7:264.
21. Bega D, et al. Yoga versus resistance training in mild to moderate severity Parkinson's disease: A 12 week pilot study. J Yoga Phys Ther. 2016;6:222.
22. Iijima M, et al. odor identification function differs between vascular Parkinsonism and akinetic-type Parkinson's disease. J Alzheimers Dis Parkinsonism. 2016;6:207.
23. Park BJ. How should we deal with Parkinson's disease? Single Cell Biol. 2016;5:129.
24. Gera G, et al. Identification of balance deficits in people with Parkinson disease; is the sensory organization test enough? Int J Phys Med Rehabil. 2016;4:322.
25. Fu LM. Genomics reveals similar and dissimilar pathogenesis between Alzheimer's and Parkinson's diseases. Biol syst Open Access. 2016;5:148.
26. Tran A, et al. The role of coffee in the therapy of Parkinson's disease. J Alzheimers Dis Parkinsonism. 2015;5:203.

27. Enrica O, et al. Low serum 25(OH)D levels in Parkinson's disease; a non-specific marker of neurodegeneration? J Alzheimers Dis Parkinsonism. 2015;5:200.
28. Perandones C, et al. Parkinson's disease in a patient with 22q11.2 deletion syndrome: The relevance of detecting mosaicisms by means of cell-by-cell evaluation techniques. Single Cell Biol. 2015;4:123.
29. Piemonte MEP, et al. A comparison between task oriented and client-centred task-oriented approaches to improve upper limb functioning in people with sub-acute stroke. J Nov Physiother. 2015;5:277.
30. Piemonte MEP, et al. Extensive training promotes performance improvement but not automaticity in patients with Parkinson's disease. J Neurol Neurophysiol. 2015;6:324.
31. Farheen SA, et al. Translational science of psychosis in Parkinson's disease. Clin Depress. 2015;1:102.
32. Cocco T and Papa S. Molecular targets for improvement of Parkinson's disease therapy. Brain Disord Ther. 2015;4:173.
33. Gambhir PK. How well can a person with Parkinson's swallow? Int J Neurorehabilitation. 2015;2:e114.
34. Díaz M, et al. Assessment of the protective capacity of nanosomes of quercetin in an experimental model of Parkinson's disease in the rat. Gen Med (Los Angel). 2015;3:207.
35. Deng X, et al. Adverse effects were not the main causes for rotigotine patch withdrawal in Parkinson's disease. J Alzheimers Dis Parkinsonism. 2015;5:195.
36. Sinelnyk AA, et al. Non-motor symptoms in parkinson's disease and efficacy of treatment in a complex therapy using fetal stem cells. J Stem Cell Res Ther. 2015;5:300.
37. Bokhari FA. Non-wolf Parkinson white (wpw) pre-excitation syndrome. Angiol. 2015;3:152.
38. Dow CT. Parkinson's - just another infectious disease. J Neuroinfect Dis. 2015;6:183.
39. Connor MO, et al. The relationship between strength and balance in individuals with Parkinson's disease. J Neurol Disord. 2015;3:239.
40. Ryan JJ, et al. Temporal disorientation base rates in Alzheimer's disease and Parkinson's disease. J Gerontol Geriat Res. 2015;4:221.
41. Pallanti S and Marras A. Transcranial magnetic stimulation treatment for motor symptoms in Parkinson's disease: a review of two decades of studies. Alzheimers Disease & Parkinsonism. 2015;5:191.
42. Morris EM, et al. The health profile of people living with Parkinson's disease managed in a comprehensive care setting. Aging Sci. 2015;3:135.
43. Salama M. MTOR silencing in Parkinson's disease both *in vitro* and *in vivo*. Brain Disord Ther. 2015;4:167.
44. Maiti R and Rodríguez HG. Phenology, morphology and variability in pollen viability of four woody species (cordiaboissieri, parkinsonia texana, parkinsonia aculeate and leucophyllum frutescens) exposed to environmental temperature in linares, northeast of Mexico. Forest Res. 2015;S1:002.
45. Hatzifilippou E, et al. High levels of anti-ganglioside antibodies in patients with Parkinson's disease associated with cognitive decline. Int J Neurorehabilitation. 2015;2:159.
46. Vadivelan M. Parkinson's disease. J Sleep Disord Ther. 2015;4:200.
47. Petrosyan TR. Bacterial melanin as a potential targeted therapy for the Parkinson's disease. Pigmentary Disorders. 2015;2:173.
48. Bagchi A, et al. Organic farming practice for quality improvement of tea and its anti-parkinsonism effect on health defense. J Phys Chem Biophys. 2015;5:178.
49. Shiina A, et al. Risk factors for psychiatric complications after deep brain stimulation in patients with Parkinson's disease: An observational study. J Neurol Disord. 2015;3:218.

50. Daniela AP, et al. Markers of Parkinson's disease progression using cerebrovascular, autonomic and small fiber polyneuropathy features. J Neurol Disord. 2015;3:217.
51. Fritsch T, et al. L-DOPA-induced disinhibition in Parkinson disease: More than agonistic behavior. Biol Syst. 2015;2:115.
52. Werner FM and Covenas R. Treatment of psychotic symptoms in Parkinson's disease. J Cytol Histol. 2015;6:e115.
53. Stephenson D, et al. Alzheimer's and Parkinson's diseases face common challenges in therapeutic development: Role of the precompetitive consortium, coalition against major diseases. J Alzheimers Dis Parkinsonism. 2015;5:183.
54. Utkin YN, et al. What animal models of Parkinsonism tell us about the distinct nicotinic acetylcholine receptors involved in pathogenesis? J Alzheimers Dis Parkinsonism. 2015;5:181.
55. Calderón-Garcidueñas L, et al. The intestinal barrier in air pollution-associated neural involvement in Mexico City residents: Mind the gut, the evolution of a changing paradigm relevant to Parkinson disease risk. J Alzheimers Dis Parkinsonism. 2015;5:179.
56. Devasena T and Francis AAP. Nanotoxicity-induced Alzheimer disease and Parkinsonism: Not further than diagnosis. J Alzheimers Dis Parkinsonism. 2015;5:178.
57. Yamamoto T, et al. Assessment of a new magnetic device to monitor swallowing in Parkinson's disease. J Neurol Neurophysiol. 2015;6:267.
58. Santiago JA, et al. Understanding the role diet plays in Parkinson's disease could lead to better disease management. Clin Exp Pharmacol. 2015;5:e135.
59. Werner FM and Covenas R. Might combined gabaa agonists and NMDA antagonists have a therapeutic and maybe a prophylactic effect in Alzheimer's and Parkinson's disease? J Cytol Histol. 2015;6:298.
60. Olalekan O and Sanya OJ. NMDA R/vdr in fish melanocytes; receptor targeted therapeutic model and mechanism in Parkinson's disease. J Biomol Res Ther. 2014;3:114.
61. Arkun K, et al. Effect of lewy bodies on mitochondrial DNA copy numbers and deletion burden in Parkinson's disease substantia nigra neurons. J Alzheimers Dis Parkinsonism. 2015;5:175.
62. Tortolero GS, et al. EEG findings in diffuse lewy body disease and Parkinson's disease with dementia. Brain Disord Ther. 2015;4:156.
63. Wang XH, et al. Impact of deep brain stimulation therapy on autonomic disturbances and related symptoms of Parkinson's disease. Brain Disord Ther. 2015;4:150.
64. Stephens SJ, et al. Fluoxetine-induced atypical serotonin syndrome with hallucinations masquerading as a Parkinsonian syndrome. Fam Med Med Sci Res. 2014;3:147.
65. Mohammed NB, et al. Single dose does matter! An interesting case of Parkinson's hyperpyrexia syndrome. J Neurol Disord. 2014;2:191.
66. Oguro H, et al. Randomized trial of repetitive transcranial magnetic stimulation for apathy and depression in Parkinson's disease. J Neurol Neurophysiol. 2014;5:242.
67. Ono S. FMT-PET for the early diagnosis of Parkinson's disease. J Neurol Disord. 2014;2:i104.
68. McDonald KR, et al. Personality style in behavioural disturbances in Parkinson's disease. J Neurol Neurophysiol. 2014;5:251.
69. Haram A, et al. Clinical correlates of RBD in early Parkinson disease. J Alzheimers Dis Parkinsonism. 2014;4:174.

70. Okada Y, et al. Rehabilitation for postural deformities in Parkinson's disease: An update and novel findings. J Nov Physiother. 2014;4:233.
71. Okada Y, et al. In-home posture evaluation and visual feedback training to improve posture with a kinect-based system in Parkinson's disease. J Nov Physiother. 2014;4:232.
72. Vanessa KH, et al. Forced exercise for freezing of gait in post stn dbs Parkinson's disease patients. J Alzheimers Dis Parkinsonism. 2014;4:171.
73. Whitesman P. Preliminary set theory-type analysis of proteins associated with Parkinson's disease. J Alzheimers Dis Parkinsonism. 2014;4:170.
74. Bitner A, et al. The role of multidrug interactions in the safety of pharmacotherapy for concomitant Parkinson's disease and arterial hypertension in Poland. J Pharmacovigilance. 2014;2:151.
75. Barboza NM, et al. The effect of an exercise-based intervention to the quality of life of patients suffering from Parkinson's disease: Prospective study. J Yoga PhysTher. 2014;4:170.
76. Turner TH, et al. Epidermal growth factor (EGF) is associated with memory and executive functioning in progressed Parkinson's disease. J Alzheimers Dis Parkinsonism. 2014;4:164.
77. Hanby MF, et al. Emotional and cognitive processing deficits in people with Parkinson's disease and apathy. J Alzheimers Dis Parkinsonism. 2014;4:156.
78. Camargo CHF, et al. Orthostatic hypotension and its relationship to the clinical course of patients with Parkinson's disease. J Alzheimers Dis Parkinsonism. 2014;4:155.
79. Seitz RJ, et al. Monitoring of visuomotor coordination in healthy subjects and patients with stroke and Parkinson's disease: An application study using the PABLOR-device. Int J Neurorehabilitation. 2014;1:113.
80. Bryan Lieber BA, et al. Motion sensors to assess and monitor medical and surgical management of Parkinson's disease. Int J Phys Med Rehabil. 2014;2:221.
81. Leroi I, et al. Apathy and emotional blunting in Parkinson's disease. Brain Disord Ther. 2014;3:141.
82. Lu J. Modeling Parkinson's disease with human induced pluripotent stem cells. Clon Transgen. 2014;3:e113.
83. Werner FM and Covenas R. Classical neurotransmitters and neuropeptides involved in Parkinson's disease: A multi-neurotransmitter system. J Cytol Histol. 2014;5:266.
84. Byl N, et al. Aerobic exercise enabled with rehabilitation technology improves mobility and balance of patients with Parkinson's disease: A quality assurance report. Int J Phys Med Rehabil. 2014;2:220.
85. Lieberman A. Falls in Parkinson disease: The relevance of short steps. J Nov Physiother. 2014;4:209.
86. Sadek HL, et al. The inflammatory cytokines in the pathogenesis of Parkinson's disease. J Alzheimers Dis Parkinsonism. 2014;4:148.
87. Suvorit SB, et al. Postencephalitic Parkinsonism in a patient with mumps infection: A case report. J Neuroinfect Dis. 2014;5:162.
88. Joanna C. Rehabilitation procedures aimed at decreasing motor symptoms in Parkinson's disease. Int J Phys Med Rehabil. 2014;S5:009.
89. Wheeler CJ, et al. T-Lymphocyte deficiency exacerbates behavioral deficits in the 6-ohda unilateral lesion rat model for Parkinson's disease. J Neurol Neurophysiol. 2014;5:209.
90. Mao CJ, et al. Prominent non-motor symptoms in patients with Parkinson's disease and pain. J Neurol Neurophysiol. 2014;5:208.

91. Mally J. Non-invasive brain stimulation and its supposed site of action in the rehabilitation of Parkinson's disease and stroke. Int J Neurorehabilitation. 2014;1:e103.
92. Miyazaki Y, et al. MIBG myocardial scintigraphy can predict the occurrence of wearing-off phenomenon in early-stage Parkinson's disease . J Neurol Disord. 2014;2:154.
93. Mehanna R. Cognitive changes after deep brain stimulation in Parkinson's disease: a critical review. Brain Disord Ther. 2014;3:116.
94. Blanchet PG and Hoffman PR. Factors influencing the effects of delayed auditory feedback on dysarthric speech associated with Parkinson's disease. Commun Disord Deaf Stud Hearing Aids. 2014;2:106.
95. Tomic S, et al. What most influence quality of sleep in Parkinson's disease patients? J Neurol Disord. 2014;2:152.
96. Lieberman A, et al. Comparison of Parkinson's disease patients who fell once with patients who fell more than once (recurrent fallers). J Alzheimers Dis Parkinsonism. 2014;4:140.
97. Pompeu JE, et al. Safety, feasibility and effectiveness of balance and gait training using Nintendo Wii Fit Plus™ on unstable surface in patients with Parkinson's disease: A pilot study. J Alzheimers Dis Parkinsonism. 2014;4:136.
98. Guimarães J, et al. Evaluation of metabolic state in striatal rat model of Parkinson's disease: Before and after deep brain stimulation. J Obes Weight Loss Ther. 2014;4:205.
99. Ivana Scovassi A. Parkinson's disease: New insights. Biochem Pharmacol (Los Angel). 2013;2:e146.
100. Wesnes KA, Burn DJ. Compromised object pattern separation performance in Parkinson's disease suggests dentate gyrus neurogenesis may be compromised in the condition. 2013.